FDA Approves New Interchangeable Biosimilar to Pertuzumab By Ogkologos - December 3, 2025 334 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory... March 18, 2021 27-Year-Old Diagnosed with Cancer at 20 Weeks Pregnant Gives Birth Amid... July 3, 2020 Boy Shaves Head To Support Friend Going Through Cancer October 1, 2021 Man Pushes Daughter To Safety Before Speeding Car Hits Him Instead:... March 29, 2019 Load more HOT NEWS How the National Cancer Act Has Made a Difference in Cancer... Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In... Mediterranean Diet Associated with a Higher Probability of Response in Patients... OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally...
